Published in Haematologica on July 01, 2010
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging (2015) 0.90
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica (2011) 0.82
Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells. Eur J Nucl Med Mol Imaging (2014) 0.81
The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma. Indian J Nucl Med (2012) 0.78
The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. Oncotarget (2016) 0.76
Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria. Asia Ocean J Nucl Med Biol (2015) 0.75
The role of 18F-FDG PET/CT in pediatric lymph-node acute lymphoblastic leukemia involvement. Radiol Case Rep (2015) 0.75
Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist (2015) 0.75
The role of FDG-PET in Hodgkin lymphoma. Contemp Oncol (Pozn) (2017) 0.75
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
Positron-emission tomography and assessment of cancer therapy. N Engl J Med (2006) 5.43
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood (2005) 2.92
Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma (2009) 2.81
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol (2009) 2.05
Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma (2009) 1.66
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol (2005) 1.66
Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program (2003) 1.56
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica (2006) 1.45
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer (2006) 1.36
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 1.35
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res (2005) 1.32
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood (1998) 1.32
Role of positron emission tomography in lymphoma. J Clin Oncol (2005) 1.26
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol (2006) 1.16
Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood (2007) 1.12
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res (2008) 0.97
Residual mass in lymphoma may not be residual disease. J Clin Oncol (1988) 0.92
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol (2009) 0.90
A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma. Haematologica (2010) 0.87
Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2008) 0.78
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med (2011) 4.50
Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma (2009) 2.81
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood (2009) 2.54
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol (2006) 1.75
International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med (2013) 1.63
False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol (2004) 1.46
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol (2010) 1.42
Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma (2013) 1.39
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood (2009) 1.36
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging (2013) 1.24
Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation (2013) 1.18
Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma (2010) 1.16
Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol (2003) 1.16
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol (2008) 1.10
Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma (2012) 1.09
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica (2008) 1.04
Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. Biol Blood Marrow Transplant (2012) 0.98
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging (2014) 0.96
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood (2013) 0.95
Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift? J Nucl Med (2013) 0.92
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol (2007) 0.91
FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging (2015) 0.90
A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. Clin Lymphoma (2004) 0.85
Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand? Leuk Lymphoma (2009) 0.84
Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres. Br J Haematol (2005) 0.84
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. BMC Cancer (2012) 0.84
Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol (2007) 0.84
Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014. Leuk Lymphoma (2015) 0.83
Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT. Medicine (Baltimore) (2014) 0.79
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. Med Oncol (2006) 0.78
High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia. Blood (2004) 0.77
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma (2011) 0.76
Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt? Haematologica (2012) 0.75
Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk (2011) 0.75
Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse. Haematologica (2005) 0.75